Clinical Profile of Oprozomib and Ixazomib in Relapsed or Refractory MM
Kumar S et al. Long-term ixazomib maintenance is tolerable and improves depth of response following ixazomib-lenalidomide-dexamethasone induction in patients (pts) with previously untreated multiple myeloma (MM): Phase 2 study results. Proc ASH 2014; Abstract 82.
Vij R et al. Clinical profile of single-agent oprozomib in patients (Pts) with multiple myeloma (MM): Updated results from a multicenter, open-label, dose escalation Phase 1b/2 study. Proc ASH 2014; Abstract 34.
Dr Landgren is Chief of the Myeloma Service at Memorial Sloan Kettering Cancer Center in New York, New York.
|